CR20150638A - Marcador para trastornos de la esfingomielinasa ácida y sus usos - Google Patents
Marcador para trastornos de la esfingomielinasa ácida y sus usosInfo
- Publication number
- CR20150638A CR20150638A CR20150638A CR20150638A CR20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disorders
- acid sphingomyelinase
- marker
- asm
- treatment
- Prior art date
Links
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 title abstract 4
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 title abstract 4
- 239000003550 marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
Abstract
La presente descripción proporciona métodos de evaluación, diagnóstico, control y/o tratamiento de trastornos de la esfingomielinasa ácida (ASM), tales corno la enfermedad deNiemann-Pick. En particular, los métodos abarcan técnicas paradiagnóstico y/o tratamiento mejorados de un trastorno de la ASM,por ejemplo usando terapia de sustitución de enzimas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832302P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041405 WO2014197859A1 (en) | 2013-06-07 | 2014-06-06 | Marker for acid sphingomyelinase disorders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150638A true CR20150638A (es) | 2016-02-08 |
Family
ID=51062988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150638A CR20150638A (es) | 2013-06-07 | 2015-12-04 | Marcador para trastornos de la esfingomielinasa ácida y sus usos |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10022428B2 (es) |
| EP (2) | EP3584580A1 (es) |
| JP (4) | JP6457501B2 (es) |
| KR (3) | KR102228367B1 (es) |
| CN (2) | CN105474017A (es) |
| AU (4) | AU2014274670B2 (es) |
| BR (1) | BR112015030099A2 (es) |
| CA (1) | CA2914751C (es) |
| CL (1) | CL2015003563A1 (es) |
| CR (1) | CR20150638A (es) |
| DK (1) | DK3004896T3 (es) |
| EA (1) | EA035342B1 (es) |
| ES (1) | ES2762608T3 (es) |
| HK (1) | HK1217534A1 (es) |
| HR (1) | HRP20192246T1 (es) |
| HU (1) | HUE047863T2 (es) |
| IL (3) | IL284102B2 (es) |
| LT (1) | LT3004896T (es) |
| MA (1) | MA38638B1 (es) |
| MX (1) | MX370570B (es) |
| MY (1) | MY185990A (es) |
| NZ (1) | NZ754328A (es) |
| PH (1) | PH12015502687A1 (es) |
| PL (1) | PL3004896T3 (es) |
| PT (1) | PT3004896T (es) |
| RS (1) | RS59677B1 (es) |
| SG (2) | SG10201709925SA (es) |
| SI (1) | SI3004896T1 (es) |
| UA (1) | UA120591C2 (es) |
| WO (1) | WO2014197859A1 (es) |
| ZA (1) | ZA201508630B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3004896T (lt) * | 2013-06-07 | 2020-01-10 | Genzyme Corporation | Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas |
| JP6984854B2 (ja) * | 2015-10-08 | 2021-12-22 | 国立大学法人千葉大学 | ニーマン・ピック病ｃ型を予防または治療するための医薬組成物 |
| PL3672622T3 (pl) * | 2017-08-24 | 2024-04-02 | Genzyme Corporation | Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| WO2024026390A2 (en) * | 2022-07-28 | 2024-02-01 | Wylder Nation Foundation | Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082781A (en) | 1976-06-04 | 1978-04-04 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide |
| US4039388A (en) | 1976-06-04 | 1977-08-02 | The United States Of America As Represented By The Government | Diagnostic test for Niemann-Pick disease |
| US5773278A (en) * | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| WO2002018539A2 (en) | 2000-08-25 | 2002-03-07 | Lysometrix Corporation | Method for assaying the activity of lysosomal enzymes |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7615224B2 (en) | 2004-12-02 | 2009-11-10 | Women's And Children's Hospital | Multiplex-bead complex for determination of lysosomal storage disorders |
| JP2006214731A (ja) * | 2005-02-01 | 2006-08-17 | Institute Of Physical & Chemical Research | スフィンゴミエリンの検出方法 |
| JP2009519713A (ja) | 2005-12-15 | 2009-05-21 | ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク | 血漿中及び組織中のスフィンゴエミリン及びホスファチジルコリンの酵素的測定方法 |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| KR102608551B1 (ko) * | 2009-08-28 | 2023-12-04 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| JP2013002933A (ja) | 2011-06-16 | 2013-01-07 | Hitachi Plant Technologies Ltd | ３次元測位システム |
| JP6243846B2 (ja) * | 2011-11-15 | 2017-12-06 | セントジーン アーゲー | ニーマン・ピック病の診断のための方法 |
| ES2731920T3 (es) * | 2013-05-14 | 2019-11-19 | Centogene Ag | Método para el diagnóstico de la enfermedad de Niemann-Pick |
| LT3004896T (lt) * | 2013-06-07 | 2020-01-10 | Genzyme Corporation | Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas |
-
2014
- 2014-06-06 LT LTEP14735056.5T patent/LT3004896T/lt unknown
- 2014-06-06 IL IL284102A patent/IL284102B2/en unknown
- 2014-06-06 IL IL298675A patent/IL298675A/en unknown
- 2014-06-06 CA CA2914751A patent/CA2914751C/en active Active
- 2014-06-06 SI SI201431434T patent/SI3004896T1/sl unknown
- 2014-06-06 BR BR112015030099A patent/BR112015030099A2/pt active Search and Examination
- 2014-06-06 CN CN201480043918.2A patent/CN105474017A/zh active Pending
- 2014-06-06 US US14/895,472 patent/US10022428B2/en active Active
- 2014-06-06 MA MA38638A patent/MA38638B1/fr unknown
- 2014-06-06 EP EP19191053.8A patent/EP3584580A1/en active Pending
- 2014-06-06 NZ NZ754328A patent/NZ754328A/en unknown
- 2014-06-06 KR KR1020167000011A patent/KR102228367B1/ko active IP Right Grant
- 2014-06-06 UA UAA201600158A patent/UA120591C2/uk unknown
- 2014-06-06 SG SG10201709925SA patent/SG10201709925SA/en unknown
- 2014-06-06 KR KR1020217025969A patent/KR102434244B1/ko active IP Right Grant
- 2014-06-06 ES ES14735056T patent/ES2762608T3/es active Active
- 2014-06-06 PL PL14735056T patent/PL3004896T3/pl unknown
- 2014-06-06 RS RS20191627A patent/RS59677B1/sr unknown
- 2014-06-06 MX MX2015016844A patent/MX370570B/es active IP Right Grant
- 2014-06-06 DK DK14735056.5T patent/DK3004896T3/da active
- 2014-06-06 EA EA201592265A patent/EA035342B1/ru not_active IP Right Cessation
- 2014-06-06 PT PT147350565T patent/PT3004896T/pt unknown
- 2014-06-06 EP EP14735056.5A patent/EP3004896B1/en active Active
- 2014-06-06 KR KR1020217007269A patent/KR102292298B1/ko active IP Right Grant
- 2014-06-06 MY MYPI2015704368A patent/MY185990A/en unknown
- 2014-06-06 CN CN202210555370.6A patent/CN115128287A/zh active Pending
- 2014-06-06 HU HUE14735056A patent/HUE047863T2/hu unknown
- 2014-06-06 AU AU2014274670A patent/AU2014274670B2/en active Active
- 2014-06-06 WO PCT/US2014/041405 patent/WO2014197859A1/en active Application Filing
- 2014-06-06 SG SG11201509622WA patent/SG11201509622WA/en unknown
- 2014-06-06 JP JP2016518053A patent/JP6457501B2/ja active Active
-
2015
- 2015-11-23 ZA ZA2015/08630A patent/ZA201508630B/en unknown
- 2015-12-01 PH PH12015502687A patent/PH12015502687A1/en unknown
- 2015-12-04 CR CR20150638A patent/CR20150638A/es unknown
- 2015-12-04 CL CL2015003563A patent/CL2015003563A1/es unknown
- 2015-12-06 IL IL242964A patent/IL242964B/en unknown
-
2016
- 2016-05-11 HK HK16105373.8A patent/HK1217534A1/zh unknown
-
2018
- 2018-02-09 AU AU2018200977A patent/AU2018200977B2/en active Active
- 2018-06-08 US US16/003,598 patent/US10888607B2/en active Active
- 2018-12-19 JP JP2018236856A patent/JP6835806B2/ja active Active
-
2019
- 2019-12-13 HR HRP20192246TT patent/HRP20192246T1/hr unknown
-
2020
- 2020-10-22 AU AU2020257114A patent/AU2020257114B2/en active Active
- 2020-12-11 US US17/119,035 patent/US11998592B2/en active Active
-
2021
- 2021-02-03 JP JP2021015390A patent/JP7414750B2/ja active Active
-
2023
- 2023-02-23 AU AU2023201062A patent/AU2023201062A1/en active Pending
- 2023-12-27 JP JP2023220385A patent/JP2024038145A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22051489A (es) | Compuestos inhibidores de metaloenzimas | |
| CY1123735T1 (el) | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης | |
| CL2019001088A1 (es) | Nuevos anticuerpos monoclonales cd47 y sus usos. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| CR20150638A (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos | |
| UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
| AR094413A1 (es) | Composiciones nutricionales conteniendo un componente neurológico y usos de las mismas | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| BR112014029346A2 (pt) | sistema e método implementado por computador para a montagem de um plano de tratamento médico | |
| BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
| CL2014002265A1 (es) | Método, aparato y sistema para diagnóstico y tratamiento de un trastorno del estado del ánimo, el cual permite aplicar estimulación vestibular giratoria, calórica u optocinética a un individuo. | |
| EA201691314A1 (ru) | Терапевтические способы и композиции | |
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| BR112018001814B8 (pt) | Unidade de contêiner médica para planejamento e/ou fabricação de um implante específicos de paciente, anatomicamente adaptados | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| BR112016006556A2 (pt) | arranjos detectáveis, sistemas para diagnóstico, e métodos para produzir e usar os mesmos | |
| BR112016003381A8 (pt) | sistema para administrar uma formulação de cantaridina a um indivíduo; dispositivo aplicador para administrar uma formulação de cantaridina a um indivíduo; usos de uma formulação de cantaridina; kit para administrar uma formulação de cantaridina a um indivíduo; formulações; e formulação de cantaridina | |
| BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
| BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 | |
| BR112017003334A8 (pt) | Variantes de desintegrina e usos farmacêuticos destas |